Glenmark Pharmaceuticals has launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), BRIDION Injection, 100 mg/mL of Merck Sharp and Dohme.

According to IQVIA sales data for the 12-month period ending May 2026, the BRIDION Injection, 100 mg/mL market achieved annual sales of approximately USD 1.6 billion.

Commenting on the launch, Marc Kikuchi, President and Business Head, North America, said, "The launch of Sugammadex Injection represents a significant addition to Glenmark's growing US injectables portfolio and strengthens our presence in the hospital and institutional segment. Achieving a Day 1 launch reflects the agility, preparedness and execution discipline behind our injectable strategy. It also underscores our ability to identify meaningful market opportunities, support greater supply reliability and expand access to high-quality and affordable medicines across the US healthcare system."

Glenmark's Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials is only approved for the indication(s) listed in Glenmark's approved label.